XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 01, 2020
Mar. 31, 2022
Nov. 30, 2020
Sep. 30, 2023
Sep. 30, 2022
Mar. 31, 2021
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2019
Dec. 31, 2022
Feb. 28, 2021
Jun. 30, 2020
Jan. 31, 2020
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries             $ 0 $ 1,999,998          
Share of net loss in Geneos       $ 0 $ 0   $ 0 $ 2,165,213          
Geneos Therapeutics, Inc.                          
Noncontrolling Interest [Line Items]                          
Ownership percentage                       47.00%  
Series A-2 One Preferred Stock                          
Noncontrolling Interest [Line Items]                          
Remeasurement of Geneos Series A-1 preferred stock   $ 165,215                      
Share of net loss in Geneos   2,165,213                      
Investment in equity method investments   $ 0               $ 1,999,998      
Geneos Therapeutics, Inc.                          
Noncontrolling Interest [Line Items]                          
Noncontrolling interest, ownership percentage by parent   28.00% 36.00% 24.00%     24.00%   61.00%   35.00%   52.00%
Geneos Therapeutics, Inc.                          
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries     $ 1,400,000           $ 1,200,000        
Stock purchase agreement, commitment of additional investment                       $ 800,000 $ 800,000
Gain on deconsolidation of investment $ 4,100,000                        
Remeasurement of Geneos Series A-1 preferred stock $ 2,400,000                        
Loss from equity method investment, recorded and allocated to investment           $ 1,500,000              
Share of net loss in Geneos           434,000              
Investment in equity method investments           0              
Geneos Therapeutics, Inc. | Series A One Preferred Stock                          
Noncontrolling Interest [Line Items]                          
Share of net loss in Geneos           819,000              
Geneos Therapeutics, Inc. | Common stock                          
Noncontrolling Interest [Line Items]                          
Investment in equity method investments           0              
Geneos Therapeutics, Inc. | Preferred stock                          
Noncontrolling Interest [Line Items]                          
Payments to acquire additional interest in subsidiaries   $ 2,000,000                      
Share of net loss in Geneos           4,200,000              
Investment in equity method investments           $ 0